ANI Pharmaceuticals Inc (NASDAQ:ANIP) is a biopharmaceutical company that focuses on developing, manufacturing, and marketing both branded and generic prescription pharmaceuticals. The company is making significant strides in the rare disease sector, aiming to become a leader in this field. ANI's competitors include other pharmaceutical companies that also target rare diseases and generic drugs.
On March 5, 2026, CAREY STEPHEN P., the Senior Vice President and Chief Financial Officer of ANI, sold 3,312 shares of the company's common stock at $75.42 each. This transaction leaves him with 189,543 shares. This sale comes as ANI sets ambitious goals for 2026, targeting over $1 billion in sales, as highlighted by CEO Nikhil Lalwani and CFO Stephen Carey at the Raymond James Conference.
ANI is leveraging cash flows from its generics segment to support its rare disease business expansion. The company expects its rare disease segment to contribute approximately 60% of total revenues by 2026. In 2025, ANI reported revenues of $883 million, a 44% increase from the previous year, and an adjusted non-GAAP EBITDA of $230 million, marking a 47% year-over-year growth.
The current stock price of ANIP is $75.60, reflecting a decrease of 1.22% or $0.93. Yesterday, the stock has traded between a low of $74.93 and a high of $76.15. Over the past year, ANIP has reached a high of $99.50 and a low of $56.71. The company's market capitalization is approximately $1.70 billion, with a trading volume of 286,215 shares on the NASDAQ exchange.
